1.
Clin Case Rep
; 12(6): e8929, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38799519
RESUMO
Serum carbohydrate antigen 19-9 (CA19-9) is used for recurrence surveillance in patients with resected pancreatic ductal adenocarcinoma (PDAC). This report describes the association of increasing CA19-9 in a male PDAC survivor with presence of prostatic hyperplasia. Unexplained elevation of CA19-9 in male PDAC survivors might be attributable to benign prostatic conditions.